#Innovation #intelligence #dualchain #integration #Nanjing #Jiangning #Hightech #Zone #holds #Innovation #Development #Conference #Pharmaceutical #Technology #Service #AllianceDetailed #InterpretationLatest #NewsHot #Events36氪
On June 11, 2021 Nanjing Innovation Week series of activities-the Jiangning High-tech Zone Medical Technology R&D Service Alliance Innovation Development Conference with the theme of “Innovation, Intelligence, Dual-Chain Integration”, was held in Nanjing Life Science and Technology Town, reviewing and summarizing Jiangning High-tech Zone The Pharmaceutical Technology R&D Service Alliance has developed in the past year and deployed the next step to organize biomedical academic reports and exchanges and seminars to further deepen the service cooperation of the biomedical industry in Jiangning High-tech Zone, accelerate the improvement and strengthening of the biomedical industry, and help Jiangning high-quality development. Strive to achieve a good start to the “14th Five-Year Plan”. Wang Guangji, academician of the Chinese Academy of Engineering, and Miao Xiumei, member of the Standing Committee of Jiangning District Committee and Secretary of the Party Working Committee of Jiangning High-tech Zone, attended the event.
Biomedicine is a characteristic leading industry in Jiangning High-tech Zone. In order to improve the biopharmaceutical service chain, strengthen the industrial chain, and promote the continuous development and growth of the biopharmaceutical industry, on May 14 last year, Jiangning High-tech Zone relied on university resources, integrated enterprise strength, and asked for market demand to establish a pharmaceutical technology research and development service alliance. At the meeting, Wang Guangji, Academician of the Chinese Academy of Engineering and Honorary Chairman of Jiangning High-tech Zone Medical Technology R&D Service Alliance, made a concluding speech. Jiangning High-tech Zone Management Committee Director Liu Guangfu delivered a speech, China Pharmaceutical University Professor and Jiangning High-tech Zone Medical Technology R&D Service Alliance Chairman Yin Lifang The construction and development of the alliance in the past year were introduced.
Since its establishment, the Jiangning High-tech Zone Pharmaceutical Technology R&D Service Alliance has actively explored operating mechanisms, strengthened industry cooperation and exchanges, strengthened core technology research, and accelerated the transformation of scientific and technological achievements. It has achieved good results in all aspects. At present, the alliance has established an organizational system including high-quality enterprises, 12 governing units of colleges and universities, and 23 member units. The business scope of the member units covers from early drug screening, pharmaceutical research, preclinical research, clinical research to registration application A one-stop R&D industrialization platform, at the same time, it provides R&D of APIs, intermediates and standard products, technology transfer, technical consultation, etc. In December last year, the alliance passed the “Nanjing Jiangning High-tech Zone Medical Technology R&D Service Alliance Management Measures (Trial)” document, and formulated a number of incentive and support policies for alliance members’ business conditions.
Since the establishment of the Jiangning High-tech Zone Medical Technology R&D Service Alliance for one year, the alliance member Hairong Pharmaceutical’s tacalciferol ointment has been approved for production, and the first generic drug in the country has been listed, bringing the gospel to the majority of psoriasis patients in China; Midu Bio has established an international Leading CAR-T tracing research technology, to carry out the first domestic polysaccharide in vivo quantitative ADME study; Jinglixin Pharmaceutical’s Class 1 innovative drug JLX001 for the treatment of ischemic cardiovascular and cerebrovascular diseases represented by ischemic stroke won the country Major new drug creation and technology major special funding… Jiangning High-tech Zone has established a medical technology research and development service alliance through the “government set up stage, enterprise singing” model to promote the development of pharmaceutical companies and the coordinated development of “government, industry, education, research and medicine”, and effectively promote the park’s biomedicine Strong industrial chains, chain supplements, chain extensions, and chain fusion will help biomedical companies embark on a fast track for the transformation of scientific and technological achievements. Last year, the member units of the Medical Technology R&D Service Alliance of Jiangning High-tech Zone applied for more than 100 national invention patents, more than 30 utility model patents, more than 10 software copyrights, and 3 PCT patents; among them, more than 20 authorized invention patents and utility model patents More than 20 pieces.
In May of this year, the Jiangning High-tech Zone Medical Technology R&D Service Alliance launched a trial application of innovative coupons for all small, medium and micro enterprises in Jiangning High-tech Zone. An innovation voucher issuance ceremony was held at the meeting on the same day. 12 biomedical companies in Jiangning High-tech Zone obtained innovation voucher, through which they can purchase inspection and testing, technology certification, qualification certification, technology transfer, intellectual property rights of member units of the Pharmaceutical Technology R&D Service Alliance. As well as opening up scientific research facilities and equipment services. Representatives of three medical units in Jiangning High-tech Zone, including Hairong Medicine and Yifu Hospital Clinical Center, made exchange speeches, introduced industry hotspots and their respective situations, and talked freely about how to use the medical technology research and development service alliance to achieve better development.
In academic reports and exchanges and discussions, Sun Hongbin, professor of China Pharmaceutical University and deputy director of the State Key Laboratory, Wang Jiancheng, professor of the Department of Pharmacy, Peking University School of Pharmacy, and deputy dean of Ningbo Institute of Marine Medicine, China Pharmaceutical University, Yang Yong, Dean of the School of Clinical Pharmacy and Director of the Research Center for New Drug Safety Evaluation, and Ding Li, the head of Nanjing Kelitai Pharmaceutical Technology Co., Ltd., and a professor at China Pharmaceutical University, respectively focused on the “development of deubiquitinating enzyme USP7 inhibitors and anti-tumor “Immune activity”, “Research progress and technical bottlenecks of nucleic acid drug delivery vehicles”, “Research on new strategies for hepatocellular carcinoma treatment”, “Innovative drug interaction evaluation” and other topics, exchange views, collision ideas, discuss innovation and cooperation, and jointly explore biomedicine The road to high-quality industrial development.
In the next step, the Jiangning High-tech Zone Pharmaceutical Technology R&D Service Alliance will creatively explore a development path that integrates the industrial chain, supply chain, creation chain, capital chain, and talent chain, and circulates smoothly through the entire chain design and integrated implementation. At the same time, give full play to the advantages of the alliance’s internal resources, actively carry out key technology research, build a platform for industry-university-research exchanges and cooperation, further promote the continuous and stable cooperation of alliance members at the strategic level, and promote the high-quality development of the biomedical industry in Jiangning High-tech Zone.
This event is one of the series of activities in 2021 Nanjing Innovation Week in Jiangning High-tech Zone. During this year’s Innovation Week, Jiangning High-tech Zone will focus on leading industries and build a characteristic industrial highland. The activities held are centered on the leading industries of the park and highlight the industrial characteristics. Taking the biomedical industry as an example, focusing on the creation of the “Jiangning Pharmaceutical Valley”, Jiangning High-tech Zone will focus on the development of the biomedical industry and will host more than 4 various thematic events. Through activities, the park will gather talents, enterprises, and elements, give play to the wisdom of high-end think tanks, shape the atmosphere of industrial development, and display the results of industrial agglomeration.